Last Updated on October 10, 2024 by The Health Master
New Delhi: The apex price regulator authority, the National Pharmaceutical Pricing Authority (NPPA), has cancelled the Request for Proposal for conducting the study entitled “To study the drug pricing policies of different countries/ region and lessons learned from these countries/ regions in terms of access to medicine at affordable prices” .
The Authority cited “administrative exigencies” as the reason for cancelling the Request for Proposal. In addition, it has requested that all bidders who have placed bids pick up their bid documents in person by visiting the NPPA’s Deputy Director at the office.
Earlier, it was reported that the apex price regulator authority, the National Pharmaceutical Pricing Authority (NPPA), had invited a proposal for conducting a study on “the drug policies of different countries to access medicine at affordable prices.”
For the same, the NPPA released a public notice inviting tenders in the form of a Request for Proposal (RFP) for conducting the study entitled as “To study the drug pricing policies of different countries/ region and lessons learnt from these countries/ regions in terms of access to medicine at affordable prices.”
As per the terms of reference given in the invitation letter, the objectives of the assessment studies were to understand the drug pricing methodology adopted in the international market and to learn from the lessons learnt or best practises from various countries or regions in terms of availability and affordability of medicine.
The scope of work was to examine regulatory policies or frameworks on drug pricing in at least ten countries, to examine the operational implementation of drug pricing policies in various countries and identify best practises or lessons learned, and to examine other policy aspects that affect the availability and affordability of medicine in these countries.
However, according to a recent NPPA tender notice released on February 21, 2022, this request for a proposal for the above-mentioned study has been terminated due to administrative demand.
Accordingly, through the notice published by the apex price regulator authority, NPPA, on February 21, 2022, the authority stated “all bidders who have submitted their bids in response to said RFP are requested to collect their bid documents personally by visiting the NPPA office/ undersigned.”
In addition, the notice further added, “Bidders are requested to ensure that the representative, who is coming to collect the documents, is carrying a letter authorizing him/her to collect the documents on behalf of their organization.
The letter must be on the organization letterhead and must contain a specimen signature of the representative sent to collect bid documents along with other details such as tender no. date and bidder’s name, etc.”
Govt listed 213 drugs for which procurement agencies could not find local manufacturers
USFDA gives nod to Lupin for Sevelamer Hydrochloride Tablets, 800 mg
USFDA declines to approve Gilead’s HIV drug on this concern
Why these Pharma Companies are realigning their India operations
USFDA approves this drug for bone marrow cancer treatment
NDPS Exporters and Importers to register with ICEGATE portal: CBN
USFDA gives nod to Unichem Laboratories for Divalproex Sodium
20 projects worth Rs. 840 crore for PLI scheme for Bulk drugs
Drug recall: Aurobindo, Sun Pharma recall these products
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
